ESSA Pharma (EPIX)
(Delayed Data from NSDQ)
$6.40 USD
-0.43 (-6.30%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $6.57 +0.17 (2.66%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for ESSA Pharma Inc falls in the month of September.
All items in Millions except EPS data.
9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 32 | 37 | 37 | 24 | 13 |
Income After Depreciation & Amortization | -32 | -37 | -37 | -24 | -13 |
Non-Operating Income | 6 | 2 | 0 | 0 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -27 | -35 | -37 | -24 | -10 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -27 | -35 | -37 | -23 | -10 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -27 | -35 | -37 | -23 | -10 |
Depreciation Footnote | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -32 | -37 | -37 | -24 | -13 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -32 | -37 | -37 | -24 | -13 |
Earnings Per Share Data | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Average Shares | 44.09 | 44.04 | 38.48 | 22.44 | 8.43 |
Diluted EPS Before Non-Recurring Items | -0.60 | -0.80 | -0.96 | -1.04 | -1.46 |
Diluted Net EPS (GAAP) | -0.60 | -0.80 | -0.96 | -1.04 | -1.24 |
Fiscal Year end for ESSA Pharma Inc falls in the month of September.
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 7.60 | 7.16 | 8.91 | 8.21 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -7.60 | -7.16 | -8.91 | -8.21 |
Non-Operating Income | NA | 1.63 | 1.67 | 1.61 | 1.15 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -5.96 | -5.48 | -7.30 | -7.06 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -5.96 | -5.48 | -7.30 | -7.06 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -5.96 | -5.48 | -7.30 | -7.06 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 44.13 | 44.09 | 44.09 | 44.09 |
Diluted EPS Before Non-Recurring Items | NA | -0.14 | -0.12 | -0.17 | -0.16 |
Diluted Net EPS (GAAP) | NA | -0.14 | -0.12 | -0.17 | -0.16 |